(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 February 2005 (10.02.2005)

PCT

(10) International Publication Number
WO 2005/012360 A2

(51) International Patent Classification[7]: C07K 16/10, C12N 15/13, 15/63, 5/10, A61K 39/215, G01N 33/68, A61P 31/14

(21) International Application Number: PCT/EP2004/051568

(22) International Filing Date: 21 July 2004 (21.07.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

PCT/EP03/50328	22 July 2003 (22.07.2003)	EP
PCT/EP03/50391	1 September 2003 (01.09.2003)	EP
PCT/EP03/50723	16 October 2003 (16.10.2003)	EP
PCT/EP03/50883	24 November 2003 (24.11.2003)	EP
PCT/EP03/50943	4 December 2003 (04.12.2003)	EP
PCT/EP04/050067	2 February 2004 (02.02.2004)	EP
PCT/EP04/050127	13 February 2004 (13.02.2004)	EP
PCT/EP04/050334	19 March 2004 (19.03.2004)	EP
PCT/EP04/050464	7 April 2004 (07.04.2004)	EP
PCT/EP04/050516	14 April 2004 (14.04.2004)	EP
PCT/EP04/050643	29 April 2004 (29.04.2004)	EP

(71) Applicant *(for all designated States except US)*: **CRUCELL HOLLAND B.V.** [NL/NL]; Archimedesweg 4, NL-2333 CN Leiden (NL).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **TER MEULEN, Jan, Henrik** [DE/DE]; Gerhard-Jahn-Platz 17, 35037 Marburg (DE). **DE KRUIF, Cornelis Adriaan** [NL/NL]; Westerlaan 40, NL-3731 EL De Bilt (NL). **VAN DEN BRINK, Edward Norbert** [NL/NL]; Burgemeester van Bruggenstraat 21, NL-1165 NS Halfweg (NL). **GOUDSMIT, Jaap** [NL/NL]; Koninginneweg 4, NL-1075 CX Amsterdam (NL).

(74) Common Representative: **CRUCELL HOLLAND B.V.**; Attn. KLEIN, Bart, Arcimedesweg 4, P.O. Box 2048, NL-2301 CA Leiden (NL).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)*

— *of inventorship (Rule 4.17(iv)) for US only*

Published:

— *without international search report and to be republished upon receipt of that report*

— *with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: BINDING MOLECULES AGAINST SARS-CORONAVIRUS AND USES THEREOF

(57) Abstract: The present invention provides binding molecules that specifically bind to SARS-CoV, nucleic acid molecules encoding the binding molecules, compositions comprising the binding molecules and methods of identifying or producing the binding molecules. The binding molecules are capable of specifically binding to SARS-CoV and can be used in the diagnosis, prophylaxis and/or treatment of a condition resulting from SARS-CoV.

WO 2005/012360 A2